The insights of Let-7 miRNAs in oncogenesis and stem cell potency

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 9, 2016, Pages 1779-1788

  Sun, Xin ^a   Liu, Jian ^a   Xu, Chongwen ^a   Tang, Shou Ching ^b,c   Ren, Hong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

anti cancer research; cancer stem cells; clinical application; DNA methylation; Let 7 miRNAs; non coding RNAs; regulatory loops

Indexed keywords

ARGONAUTE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 6; E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 4; LET 7 MIRNA; MICRORNA; MICRORNA 29; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; RETINA S ANTIGEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; CELL SELF-RENEWAL; DNA METHYLATION; EXOSOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW;

EID: 84982273008     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12861     Document Type: Review

References (84)

1. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10: 155–9.
2. Wang R, Lv Q, Meng W, et al. Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors. J Thorac Dis. 2014; 6: 829–37.
3. Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K, Li H. Circular RNA: A new star of noncoding RNAs. Cancer Letters. 2015; 365: 141-8.
4. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19: 141-57.
5. Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015; 518: 107–10.
6. Yang X, Xie X, Xiao Y-F, et al. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 2015; 360: 119–24.
7. Parolia A, Crea F, Xue H, et al. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Mol Cancer. 2015; 14: 46.
8. Sun X, Jiao X, Pestell TG, et al. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene. 2014; 33: 4967–77.
9. Boyerinas B, Park SM, Hau A, et al. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010; 17: F19–36.
10. Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol. 2014; 15: 243–56.
11. Sun X, Qin S, Fan C, et al. Let-7: a regulator of the ERalpha signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep. 2013; 29: 2079–87.
12. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131: 1109–23.
13. Li Z, Shi K, Guan L, et al. ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett. 2010; 584: 2291–7.
14. Dhar SK, Tangpong J, Chaiswing L, et al. St Clair DK. Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stages. Cancer Res. 2011; 71: 6684–95.
15. Zhao Y, Deng C, Wang J, et al. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011; 127: 69–80.
16. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007; 21: 1025–30.
17. Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013; 21: 185–91.
18. Thornton JE, Chang H-M, Piskounova E, et al. Lin28-mediated control of let-7 microRNA expression by alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7). RNA. 2012; 18: 1875–85.
19. Hagan JP, Piskounova E, Gregory RI. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol. 2009; 16: 1021–5.
20. Wang T, Liu Z, Guo S, et al. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget. 2014; 5: 3611–21.
21. Jilkine A, Gutenkunst RN. Effect of dedifferentiation on time to mutation acquisition in stem cell-driven cancers. PLoS Comput Biol. 2014; 10: e1003481.
22. Zisoulis DG, Kai ZS, Chang RK, et al. Autoregulation of microRNA biogenesis by let-7 and Argonaute. Nature. 2012; 486: 541–4.
23. Chatterjee S, Crozet L, Damotte D, et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res. 2014; 74: 5008–18.
24. Li H, Zheng D, Zhang B, et al. Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell carcinoma. J Transl Med. 2014; 12: 196.
25. Ha T-Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Network. 2011; 11: 135–54.
26. Vira D, Basak SK, Veena MS, et al. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012; 31: 733–51.
27. Oskarsson T, Batlle E, Massagué J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14: 306–21.
28. Rupaimoole R, Han HD, Lopez-Berestein G, et al. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011; 30: 368–70.
29. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009; 11: 228–34.
30. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87–108.
31. Worringer KA, Rand TA, Hayashi Y, Sami S, Takahashi K, Tanabe K, Narita M, Srivastava D, Yamanaka S. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell stem cell. 2014; 14: 40-52.
32. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5–29.
33. Matsubara S, Ding Q, Miyazaki Y, et al. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep. 2013; 3: 3230.
34. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells. 2010; 28: 639–48.
35. Lerner RG, Petritsch C. A microRNA-operated switch of asymmetric-to-symmetric cancer stem cell divisions. Nat Cell Biol. 2014; 16: 212–4.
36. Senoo M, Pinto F, Crum CP, et al. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007; 129: 523–36.
37. Podshivalova K, Salomon DR. microRNA regulation of T lymphocyte immunity: modulation of molecular networks responsible for T cell activation, differentiation and development. Crit Rev Immunol. 2013; 33: 435–76.
38. Dey-Guha I, Wolfer A, Yeh AC, et al. Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci USA. 2011; 108: 12845–50.
39. Sotiriou C, Neo S-Y, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003; 100: 10393–8.
40. Hannafon BN, Ding WQ. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013; 14: 14240–69.
41. Dey-Guha I, Alves CP, Yeh AC, et al. A mechanism for asymmetric cell division resulting in proliferative asynchronicity. Mol Cancer Res. 2015; 13: 223–30.
42. Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol. 2014; 90: 615–21.
43. Sun X, Tang S-C, Xu C, et al. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1. J Cell Mol Med. 2015; 19: 1357–65.
44. Casimiro MC, Wang C, Li Z, et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol. 2013; 27: 1415–28.
45. Pestell RG. New roles of cyclin d1. Am J Pathol. 2013; 183: 3–9.
46. Mittal D, Saccheri F, Vénéreau E, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010; 29: 2242–52.
47. Dapito DH, Mencin A, Gwak G-Y, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012; 21: 504–16.
48. Shi X, Zhang Y, Zheng J, et al. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal. 2012; 16: 1215–28.
49. Piskounova E, Polytarchou C, Thornton JE, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011; 147: 1066–79.
50. Abdel-Raouf TA, Ahmed A, Zaki WK, et al. Study of toll-like receptor 7 expression and interferon α in Egyptian patients with chronic hepatitis C infection and hepatocellular carcinoma. Egypt J Med Hum Genet. 2014; 15: 387–92.
51. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009; 58: 704–20.
52. Mohamed FE, Al-Jehani RM, Minogue SS, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015; 35: 1063–76.
53. Phung TL, Du W, Xue Q, et al. Akt1 and Akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015; 75: 40–50.
54. Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012; 287: 1527–37.
55. Chang H-M, Triboulet R, Thornton JE, Gregory RI. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. Nature. 2013; 497: 244-8.
56. Zielske SP, Spalding AC, Wicha MS, et al. Ablation of breast cancer stem cells with radiation. Transl Oncol. 2011; 4: 227–33.
57. So EY, Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci. 2010; 6: 675–81.
58. Oak PS, Kopp F, Thakur C, et al. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012; 131: 2808–19.
59. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, et al. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS ONE. 2013; 8: e77281.
60. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011; 146: 353–8.
61. Lagadec C, Vlashi E, Della Donna L, et al. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 2012; 30: 833–44.
62. Printz C. Radiation treatment generates therapy-resistant cancer stem cells from less aggressive breast cancer cells. Cancer. 2012; 118: 3225.
63. Qu S, Yang X, Li X, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015; 365: 141–8.
64. Lukiw WJ, Circular RNA. circRNA in Alzheimer's disease (AD). Front Genet. 2013; 4: 307.
65. Zhou X, Ruan J, Wang G, et al. Characterization and identification of microRNA core promoters in four model species. PLoS Comput Biol. 2007; 3: e37.
66. Valeri N, Vannini I, Fanini F, et al. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome. 2009; 20: 573–80.
67. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51: 881–90.
68. Duursma AM, Kedde M, Schrier M, et al. miR-148 targets human DNMT3b protein coding region. RNA. 2008; 14: 872–7.
69. Fu X, Jin L, Wang X, et al. MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proc Natl Acad Sci USA. 2013; 110: 17892–7.
70. Zhang P, Huang B, Xu X, et al. Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem Biophys Res Commun. 2013; 437: 368–73.
71. Song SJ, Ito K, Ala U, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 2013; 13: 87–101.
72. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007; 67: 1419–23.
73. Lu L, Katsaros D, de la Longrais IA, et al. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007; 67: 10117–22.
74. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS ONE. 2014; 9: e92921.
75. Shin VY, Siu JM, Cheuk I, et al. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015; 112: 1751–9.
76. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15: 6980–6.
77. Chen K, Wu K, Gormley M, et al. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. Oncotarget. 2013; 4: 923–35.
78. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA. 2013; 110: 972–7.
79. Zhou D, Shao L, Spitz DR. Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res. 2014; 122: 1–67.
80. He X, Tan X, Wang X, et al. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumour Biol. 2014; 35: 12181–8.
81. Yang F, Xue X, Bi J, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol. 2013; 139: 437–45.
82. Hu X, Guo J, Zheng L, et al. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res. 2013; 11: 240–50.
83. Li M, Marin-Muller C, Bharadwaj U, et al. MicroRNAs: control and loss of control in human physiology and disease. World J Surg. 2009; 33: 667–84.
84. Sun X, Jiang S, Liu J, et al. MiR-208a stimulates the cocktail of SOX2 and beta-catenin to inhibit the let-7 induction of self-renewal repression of breast cancer stem cells and formed miR208a/let-7 feedback loop via LIN28 and DICER1. Oncotarget. 2015; 6: 32944–54.